NCT02721589View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

April 6, 2016

Primary Completion Date

November 17, 2019

Study Completion Date

November 17, 2019

Conditions

Advanced Solid Tumors

Interventions

BIOLOGICAL

SHR-1210

A fully human monoclonal immunoglobulin (IgG4 subtype)

Trial Locations (1)

510060

Cancer Hospital Affiliated to Zhongshan University, Guangzhou

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT02721589 - A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects | Biotech Hunter | Biotech Hunter